⌕
Axogen · AXGN · Nasdaq
Tenet 54 · Mixed
Compare
$55.37−0.02%At closeTenet 54 · Mixed
$55.37−0.01 (−0.02%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Axogen (AXGN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is AXGN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● The Motley FoolNov 16, 2026 · 17:00 ET
AxoGen: 3 Key Takeaways for Long-Term Investors

AxoGen raised full-year 2026 revenue guidance to at least $290 million. Commercial payer coverage for Avance reached 96% of covered U.S. lives.…

AXGN 0.0% todayRead at source ↗
● Zacks Investment ResearchNov 12, 2026 · 13:00 ET
AxoGen (AXGN) is a Great Momentum Stock: Should You Buy?

Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out.…

AXGN 0.0% todayRead at source ↗
● Seeking AlphaNov 9, 2026 · 14:41 ET
Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript

Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript…

AXGN 0.0% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, to…

AXGN 0.0% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 12:41 ET
GMED vs. AXGN: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for those looking for under…

AXGN 0.0% todayRead at source ↗
● Seeking AlphaOct 30, 2026 · 12:25 ET
Axogen: Taking The Friction Out Of Nerve Repair

Axogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a regulatory moat for the next decade. Q3 2026 saw 26% revenue growth, 45% adjusted EBITDA growth,…

AXGN 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 10:41 ET
Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?

Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.…

AXGN 0.0% todayRead at source ↗
● MarketBeatOct 28, 2026 · 18:06 ET
AxoGen Q3 Earnings Call Highlights

AxoGen NASDAQ: AXGN reported third-quarter revenue growth of 26.2% as demand for its nerve-repair products increased across its breast, extremities, oral and maxillofacial, and head-and-neck markets. The company also rai…

AXGN 0.0% todayRead at source ↗
● Seeking AlphaOct 28, 2026 · 12:09 ET
Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript

Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript…

AXGN 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 09:36 ET
AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates

AxoGen (AXGN) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.…

AXGN 0.0% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 07:02 ETCOMPANY'S OWN WORDS
Axogen, Inc. Reports Third Quarter 2026 Financial Results

Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million…

AXGN 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 21, 2026 · 11:06 ET
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

AXGN 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 16, 2026 · 12:40 ET
GMED or AXGN: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or AxoGen (AXGN). But which of these two stocks offers value investors a better bang for their buck rig…

AXGN 0.0% todayRead at source ↗
● GlobeNewsWireOct 14, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026

ALACHUA, Fla. and TAMPA, Fla.…

AXGN 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 5, 2026 · 10:35 ET
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings es…

AXGN 0.0% todayRead at source ↗
● GlobeNewsWireOct 1, 2026 · 17:19 ETCOMPANY'S OWN WORDS
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

ALACHUA, Fla. and TAMPA, Fla.…

AXGN 0.0% todayRead at source ↗
● GuruFocusSep 22, 2026 · 20:09 ET
Axogen Inc (AXGN) Shares Fall 3.0% -- GF Value Says Still Overvalued

On September 22, 2026, Axogen Inc (AXGN) shares fell by 3.0%, closing at $44.54. The stock is currently trading within a 52-week range of $15.27 to $52.91.…

AXGN 0.0% todayRead at source ↗
● BenzingaSep 10, 2026 · 12:31 ET
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.…

AXGN 0.0% todayRead at source ↗
● Schaeffers ResearchSep 10, 2026 · 10:47 ET
2 Medical-Device Stocks Lighting Up the Options Pits

Medical-device stocks Cooper Companies Inc (NASDAQ:COO) and Axogen Inc (NASDAQ:AXGN) are both sharply lower following separate company developments, and options traders are chiming in.…

AXGN 0.0% todayRead at source ↗
● Seeking AlphaSep 10, 2026 · 10:47 ET
Axogen, Inc. (AXGN) M&A Call Transcript

Axogen, Inc. (AXGN) M&A Call Transcript…

AXGN 0.0% todayRead at source ↗
● GlobeNewsWireSep 10, 2026 · 06:01 ETCOMPANY'S OWN WORDS
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock

ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of …

AXGN 0.0% todayRead at source ↗
● GlobeNewsWireSep 10, 2026 · 06:00 ETCOMPANY'S OWN WORDS
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen's addressable market within its focus markets…

AXGN 0.0% todayRead at source ↗
● GlobeNewsWireSep 1, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference

ALACHUA, Fla. and TAMPA, Fla.…

AXGN 0.0% todayRead at source ↗
● GuruFocusAug 26, 2026 · 18:40 ET
Axogen Inc (AXGN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 64/100

On August 26, 2026, Axogen Inc (AXGN) shares rose 3.3% to a current price of $51.58, continuing a strong upward trend. Over the past year, the stock has surged…

AXGN 0.0% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA36−0.4%
INTC4−0.5%
LAW4−8.6%
ABR3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just AXGN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.